What is Zacks Research’s Forecast for PBH Q4 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research boosted their Q4 2026 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a note issued to investors on Tuesday, February 24th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.59 for the quarter, up from their prior forecast of $1.54. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.32 EPS and Q1 2028 earnings at $1.14 EPS.

Several other equities analysts have also commented on PBH. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Jefferies Financial Group reduced their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average target price of $80.60.

Prestige Consumer Healthcare Trading Up 1.3%

PBH stock opened at $70.26 on Thursday. The firm has a fifty day moving average price of $65.11 and a 200 day moving average price of $63.45. Prestige Consumer Healthcare has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The firm has a market cap of $3.32 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 2.18 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare’s quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its stake in Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after buying an additional 119,459 shares during the period. State Street Corp boosted its position in Prestige Consumer Healthcare by 1.4% in the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after buying an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after acquiring an additional 21,085 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after acquiring an additional 9,455 shares during the period. Finally, Morgan Stanley raised its stake in shares of Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after acquiring an additional 71,078 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).